Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label dose-finding study of 3-month degarelix regimens in prostate cancer
2007-001650-77Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Mar 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of degarelix in prostate cancer (PCa) (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Probability of testosterone at castration level from Day 28 through Day 364. Started Mar 2007; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2007-001650-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001650-77.